Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sending a Message: FDA Leadership Responds to McNeil Recall

This article was originally published in RPM Report

Executive Summary

Deputy Commissioner Josh Sharfstein told a House committee investigating J&J's consumer products recall that the agency is "sending a message to industry" that it is getting tougher on manufacturing compliance. Here is his prepared testimony.

You may also be interested in...

No Walk in the Park: FDA Talks Tough about Executive Accountability

If history is any guide, FDA will soon start showing its teeth as a regulatory enforcement agency. That makes this a good time for executives to refresh their memory about the doctrine of strict liability for FD&C Act violations-and to ponder the implications of the Department of Justice's recent use of the so-called Park doctrine against three top execs at Purdue Pharma.

Fostering Trust at FDA

Joshua Sharfstein left his post as principle deputy commissioner of the Food & Drug Administration in January, leaving behind a short but productive legacy of increasing the level of transparency at FDA. Just before he left to become Maryland’s Secretary of Health and Mental Hygiene, he discussed transparency at the FDA/CMS Summit for Biopharmaceutical Executives. Here are excerpts from Sharfstein’s speech.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts